ADALAT XL TABLET (EXTENDED-RELEASE)

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Kup teraz

Składnik aktywny:

NIFEDIPINE

Dostępny od:

BAYER INC

Kod ATC:

C08CA05

INN (International Nazwa):

NIFEDIPINE

Dawkowanie:

20MG

Forma farmaceutyczna:

TABLET (EXTENDED-RELEASE)

Skład:

NIFEDIPINE 20MG

Droga podania:

ORAL

Sztuk w opakowaniu:

28/98

Typ recepty:

Prescription

Dziedzina terapeutyczna:

DIHYDROPYRIDINES

Podsumowanie produktu:

Active ingredient group (AIG) number: 0115253002; AHFS:

Status autoryzacji:

CANCELLED POST MARKET

Data autoryzacji:

2020-12-09

Charakterystyka produktu

                                ADALAT XL
Page 1 of 34
PRODUCT MONOGRAPH
PR
ADALAT
® XL
®
Nifedipine extended-release tablets
20 mg, 30 mg and 60 mg nifedipine
Bayer Standard
Antianginal/Antihypertensive Agent
Manufactured by:
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Revision:
July 25, 2016
Submission Control No: 194331

2016, Bayer Inc.
® TM see www.bayer.ca/tm-mc. All other trademarks are the property of
their respective
owners.
ADALAT XL
Page 2 of 34
TABLE OF CONTENTS
PART
I:
HEALTH
PROFESSIONAL
INFORMATION ..........................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................
18
OVERDOSAGE
........................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 20
STORAGE AND STABILITY
.................................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 22
PART
II:
SCIENTIFIC
INFORMATION
................................................................................
24
PHARMACEUTICAL INFORMATION
......
                                
                                Przeczytaj cały dokument
                                
                            

Dokumenty w innych językach

Charakterystyka produktu Charakterystyka produktu francuski 25-07-2016

Wyszukaj powiadomienia związane z tym produktem